Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
61
Language
English
Published on
30/10/24
You may also be interested by these reports :
05/11/25
Demant’s Q3 organic sales slightly exceeded expectations, driven by growth in hearing care and hearing aids, though partially offset by weakness in ...
05/11/25
Fresenius delivered strong Q3 results, driven by broad-based growth across Kabi and Helios, with improving margins despite some challenges. Kabi’s ...
05/11/25
Qiagen reported better-than-expected Q3 results, with healthy growth across segments supporting the top line. Profitability also improved, prompting ...
04/11/25
bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. ...